Cargando…

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease

Adalimumab (ADA) trough level and anti-ADA antibody (AAA) positivity influence mucosal healing and loss of response in patients with inflammatory bowel disease (IBD). In this study, we clarified the correlation between ADA monitoring, including non-trough level, and real-world IBD clinical outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Masaichi, Sugimoto, Ken, Ikeya, Kentaro, Takano, Ryosuke, Matsuura, Ai, Miyazu, Takahiro, Ishida, Natsuki, Tamura, Satoshi, Tani, Shinya, Yamade, Mihoko, Hamaya, Yasushi, Iwaizumi, Moriya, Osawa, Satoshi, Furuta, Takahisa, Hanai, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270420/ https://www.ncbi.nlm.nih.gov/pubmed/34242369 http://dx.doi.org/10.1371/journal.pone.0254548

Ejemplares similares

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
por: Miyazu, Takahiro, et al.
Publicado: (2021)

Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
por: Miyazu, Takahiro, et al.
Publicado: (2022)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
por: Ishida, Natsuki, et al.
Publicado: (2021)

Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
por: Ishida, Natsuki, et al.
Publicado: (2022)

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2020)

Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience
por: Ishida, Natsuki, et al.
Publicado: (2020)

Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
por: Ishida, Natsuki, et al.
Publicado: (2021)

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Tamura, Satoshi, et al.
Publicado: (2020)

Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
por: Tamura, Satoshi, et al.
Publicado: (2021)

Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
por: Ishida, Natsuki, et al.
Publicado: (2022)

Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2022)

Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study
por: Ishida, Natsuki, et al.
Publicado: (2021)

Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
por: Ishida, Natsuki, et al.
Publicado: (2020)

Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
por: Ishida, Natsuki, et al.
Publicado: (2021)

Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
por: Miyazu, Takahiro, et al.
Publicado: (2022)

Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2022)

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission
por: Takano, Ryosuke, et al.
Publicado: (2018)

A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
por: Matsuura, Tomoharu, et al.
Publicado: (2023)

Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report
por: Ishida, Natsuki, et al.
Publicado: (2020)

Intrahepatic cholangiocarcinoma in patients with primary sclerosing cholangitis and ulcerative colitis: Two case reports
por: Miyazu, Takahiro, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma
por: Mori, Taiki, et al.
Publicado: (2018)

DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection
por: Sugiyama, Tomohiro, et al.
Publicado: (2020)

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2018)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study
por: Kaneko, Masanao, et al.
Publicado: (2023)

A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
por: Yamamoto, Takayuki, et al.
Publicado: (2018)

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
por: Yamamoto, Takayuki, et al.
Publicado: (2018)

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
por: Yamamoto, Takayuki, et al.
Publicado: (2018)

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
por: Osawa, Satoshi, et al.
Publicado: (2009)

MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells
por: Suzuki, Satoshi, et al.
Publicado: (2017)

Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report
por: Ikeda, Shinya, et al.
Publicado: (2019)

Pure somatic pathogenic variation profiles for patients with serrated polyposis syndrome: a case series
por: Hidaka, Misaki, et al.
Publicado: (2022)

Methylation of CpG island promoters at ZNF625, LONRF2, SDC2 and WDR17 in a patient with numerous non-granular type laterally spreading tumors and colorectal cancer: A case report
por: Iwaizumi, Moriya, et al.
Publicado: (2022)

Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review
por: Sugimoto, Mitsushige, et al.
Publicado: (2012)

Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
por: Nakase, H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ujja6cc0mmr6lnm01jpqkiev5v